Evidence map›Paper›PMID 37963086›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2024

Viral Suppression Trajectories Destabilized After Coronavirus Disease 2019 Among US People With Human Immunodeficiency Virus: An Interrupted Time Series Analysis.

Matthew A Spinelli, Katerina A Christopoulos, Carlos V Moreira, Jennifer P Jain, Nadra Lisha, David V Glidden, Greer A Burkholder, Heidi M Crane, Adrienne E Shapiro, Jeffrey M Jacobson and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Matthew A SpinelliDivision of HIV, ID, and Global Medicine, University of California, SanFrancisco, California, USA.ORCID 0000-0001-6368-8664
Katerina A ChristopoulosDivision of HIV, ID, and Global Medicine, University of California, SanFrancisco, California, USA.
Carlos V MoreiraDivision of HIV, ID, and Global Medicine, University of California, SanFrancisco, California, USA.
Jennifer P JainDivision of Prevention Science, University of California, SanFrancisco, California, USA.
Nadra LishaDepartment of Epidemiology and Biostatistics, University of California, SanFrancisco, California, USA.
David V GliddenDepartment of Epidemiology and Biostatistics, University of California, SanFrancisco, California, USA.
Greer A BurkholderDivision of Infectious Diseases, University of Alabama at Birmingham, Birmingham,Alabama, USA.
Heidi M CraneDivision of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Adrienne E ShapiroDivision of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Jeffrey M JacobsonDivsion of Infectious Diseases, Case Western Reserve University, Cleveland, Ohio, USA.
Edward R CachayDivision of Infectious Diseases, University of California, San Diego, California, USA.
Kenneth H MayerDepartment of Medicine, Harvard University and the Fenway Institute/Fenway Health, Boston, Massachusetts, USA.
Sonia NapravnikDivision of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.
Richard D MooreDivision of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA.
Monica GandhiDivision of HIV, ID, and Global Medicine, University of California, SanFrancisco, California, USA.
Mallory O JohnsonDivision of Prevention Science, University of California, SanFrancisco, California, USA.

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI EDWIN ROBERTO ORELLANA · 1988 to 2026
$104.9M
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Latesha Ellen Elopre · 1988 to 2026
$84.1M
Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI DAVID S METZGER · 1999 to 2026
$78.6M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 1994 to 2026
$78.4M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 2001 to 2026
$57.4M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Alan David Levine · 1994 to 2026
$50.0M
University of Pennsylvania HIV Clinical Trials UnitUM1AI069534 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Ian Frank, PABLO TEBAS · 2012 to 2026
$33.0M
UNC MACS/WIHS Combined Cohort Study Clinical Research SiteU01HL146194 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Michael Bradley Drummond, Michelle Floris-Moore · 2019 to 2026
$23.2M
FIC NIH HHS D43 TW007124NHLBI NIH HHS U01 HL146194NIAID NIH HHS K23 AI140918NIAID NIH HHS K24 AI167805NIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI036214NIAID NIH HHS P30 AI036219NIAID NIH HHS P30 AI045008NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI094189NIAID NIH HHS R01 AI158013NIAID NIH HHS R01AI158013NIAID NIH HHS R24AI067039NIAID NIH HHS UM1 AI069534NIDA NIH HHS K01 DA056306NIDA NIH HHS U01DA036935NIDA NIH HHS UG3 DA058304NIMH NIH HHS P30 MH062246NIMH NIH HHS P30MH062246
6 · The paper itself

Abstract

We examined changes in the proportion of people with human immunodeficiency virus (PWH) with virologic suppression (VS) in a multisite US cohort before and since the coronavirus disease 2019 (COVID-19) pandemic. Overall, prior gains in VS slowed during COVID-19, with disproportionate impacts on Black PWH and PWH who inject drugs.

Indexed as

COVID-19HIV InfectionsHIVHumansInterrupted Time Series AnalysisHIVpeople who inject drugspost-COVID-19Racial disparitiesvirologic suppression

Identifiers

PMID37963086
PMCPMC11006098

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.